Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock

Key Points

• Elena Ridloff, a Kymera director, sold 7,400 shares on March 31 and 4,600 shares on April 1 — a total of 12,000 shares for roughly $1.02 million (7,400 at $85.37 = $631,738; 4,600 at $85.42 = $392,932), disclosed in an SEC filing.
• Kymera missed its recent quarterly estimates (EPS $(0.97) vs $(0.77) est.; revenue $2.87M vs $14.8M est., down 60.8% YoY), trades around $84.77 with a $6.92B market cap and negative margins, but carries a consensus "Moderate Buy" rating and an average target of $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $85.37, for a total value of $631,738.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The stock was sold at an average price of $85.42, for a total transaction of $392,932.00.

Kymera Therapeutics Stock Down 0.2%

Shares of KYMR traded down $0.16 during mid-day trading on Thursday, hitting $84.77. The company had a trading volume of 114,596 shares, compared to its average volume of 761,006. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The business's 50-day simple moving average is $81.01 and its 200-day simple moving average is $71.64. The stock has a market cap of $6.92 billion, a PE ratio of -23.04 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business's revenue for the quarter was down 60.8% on a year-over-year basis. During the same period last year, the company posted ($0.88) EPS. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company's stock valued at $849,000 after acquiring an additional 1,833 shares during the last quarter. Millennium Management LLC boosted its holdings in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company's stock worth $13,972,000 after purchasing an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after purchasing an additional 491,737 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock worth $40,000 after purchasing an additional 770 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Kymera Therapeutics by 343.1% during the second quarter. JPMorgan Chase & Co. now owns 207,722 shares of the company's stock worth $9,065,000 after purchasing an additional 160,848 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KYMR. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Wall Street Zen downgraded Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Kymera Therapeutics in a report on Thursday, January 22nd. Mizuho upped their target price on Kymera Therapeutics from $81.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, December 11th. Finally, Stephens increased their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.